Logo for Sensei Biotherapeutics Inc

Sensei Biotherapeutics Investor Relations Material

Latest events

Logo for Sensei Biotherapeutics Inc

Study Update

Sensei Biotherapeutics
Logo for Sensei Biotherapeutics

Q3 2024

14 Nov, 2024
Logo for Sensei Biotherapeutics

Q2 2024

6 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Sensei Biotherapeutics Inc

Access all reports
Sensei Biotherapeutics, Inc. is an immuno-oncology company dedicated to the discovery and development of next-generation therapeutics aimed at treating cancer patients. The company's innovative approach is centered on its TMAb™ (Tumor Microenvironment Activated biologics) platform, which develops conditionally active therapeutics. These therapeutics are designed to selectively disable checkpoints and other immunosuppressive signals in the tumor microenvironment, thereby unleashing T cells against tumors. Among its pipeline, the lead investigational candidate is SNS-101, a conditionally active antibody tailored to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint within the tumor's low pH environment, where VISTA suppresses T cell activity by binding the PSGL-1 receptor. The company is headquartered in Rockville, Maryland, with an additional office in Boston, Massachusetts, and its shares are listed on the Nasdaq.